These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33108950)

  • 1. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to symptomatic treatments for Alzheimer's disease.
    Cummings J
    Mol Neurodegener; 2021 Jan; 16(1):2. PubMed ID: 33441154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
    Cummings J; Zhong K
    Clin Pharmacol Ther; 2015 Nov; 98(5):483-5. PubMed ID: 26206713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist.
    Flint AJ; van Reekum R
    Can J Psychiatry; 1998 Sep; 43(7):689-97. PubMed ID: 9773218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latrepirdine for Alzheimer's disease.
    Chau S; Herrmann N; Ruthirakuhan MT; Chen JJ; Lanctôt KL
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD009524. PubMed ID: 25897825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy strategies in Alzheimer's disease].
    Lacomblez L
    Rev Prat; 1998 Nov; 48(17):1913-7. PubMed ID: 9854394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
    Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.
    Vellas B; Bain LJ; Touchon J; Aisen PS
    J Prev Alzheimers Dis; 2019; 6(3):198-203. PubMed ID: 31062835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
    Cutler NR; Sramek JJ
    Eur J Clin Pharmacol; 1995; 48(6):421-8. PubMed ID: 8582458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.
    Cummings JL; Tong G; Ballard C
    J Alzheimers Dis; 2019; 67(3):779-794. PubMed ID: 30689575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
    Otsubo Y
    Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.